Glenmark Pharmaceuticals (BOM:532296) ROE % Adjusted to Book Value : 3.00% (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals ROE % Adjusted to Book Value?

Glenmark Pharmaceuticals's ROE % for the quarter that ended in Sep. 2024 was 16.78%. Glenmark Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2024 was 5.59. Glenmark Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was 3.00%.

Glenmark Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Glenmark Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals ROE % Adjusted to Book Value Chart

Glenmark Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

13.84

7.94

8.51

2.32

-5.04

Glenmark Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-1.36	-	-18.05	-	3.00

Competitive Comparison of Glenmark Pharmaceuticals's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Glenmark Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Glenmark Pharmaceuticals ROE % Adjusted to Book Value Calculation

Glenmark Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-17.34%	/	3.44
	=	-5.04%

Glenmark Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	16.78%	/	5.59
	=	3.00%

Glenmark Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Glenmark Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » ROE % Adjusted to Book Value

Traded in Other Exchanges

GLENMARK:India

Address

B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099

Website

https://www.glenmarkpharma.com

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe, and the rest of the world.

Glenmark Pharmaceuticals Headlines

No Headlines